News | December 27, 2025
Zeon Corporation to acquire Ushio’s microfluidics biz
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
NUFYMCO BLA has been approved by the USFDA
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The expansion includes a larger technical and service team and increased local procurement
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
